SARS-CoV-2-IN-13 (compound 6) 是一种有效的 SARS-CoV-2 抑制剂，IC50 为 0.057 μM。SARS-CoV-2-IN-13 是一种氯硝柳胺类似物。SARS-CoV-2-IN-13 在人血浆和肝S9酶测定中比氯硝柳胺具有更高的稳定性，口服给药可提高生物利用度和半衰期。

SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 (compound 5) potently inhibits SARS-CoV-2 (IC50=0.057 μM). SARS-CoV-2-IN-13 shows higher stability in human plasma and liver S9 enzymes assay than niclosamide. SARS-CoV-2-IN-13 shows improved bioavailability and half-life when administered orally.

56961-10-5

C13H8Cl2N2O4

327.12

DMSO:112.5 mg/mL (343.9 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years